ROSSINI, Maurizio
 Distribuzione geografica
Continente #
NA - Nord America 22.866
EU - Europa 22.628
AS - Asia 16.464
SA - Sud America 2.209
AF - Africa 459
OC - Oceania 41
Continente sconosciuto - Info sul continente non disponibili 17
Totale 64.684
Nazione #
US - Stati Uniti d'America 22.498
RU - Federazione Russa 7.720
SG - Singapore 7.035
GB - Regno Unito 5.405
CN - Cina 4.546
IT - Italia 2.681
BR - Brasile 1.745
HK - Hong Kong 1.458
DE - Germania 1.403
VN - Vietnam 1.359
FR - Francia 1.262
SE - Svezia 1.112
IE - Irlanda 1.064
FI - Finlandia 869
KR - Corea 558
IN - India 319
UA - Ucraina 315
TR - Turchia 230
JP - Giappone 203
CA - Canada 177
NL - Olanda 166
AR - Argentina 165
BD - Bangladesh 137
NG - Nigeria 131
MX - Messico 123
PL - Polonia 113
IQ - Iraq 104
ES - Italia 102
ID - Indonesia 95
ZA - Sudafrica 84
BE - Belgio 79
AT - Austria 76
EC - Ecuador 71
CO - Colombia 57
CL - Cile 48
PK - Pakistan 47
RO - Romania 47
UZ - Uzbekistan 47
TG - Togo 43
VE - Venezuela 42
BJ - Benin 39
MA - Marocco 37
IR - Iran 36
SA - Arabia Saudita 34
AU - Australia 33
NP - Nepal 27
PY - Paraguay 27
EG - Egitto 26
KE - Kenya 25
PE - Perù 25
PH - Filippine 25
IL - Israele 23
CH - Svizzera 22
LT - Lituania 21
JO - Giordania 19
MY - Malesia 19
AZ - Azerbaigian 18
CZ - Repubblica Ceca 18
GR - Grecia 18
AE - Emirati Arabi Uniti 16
DZ - Algeria 16
PT - Portogallo 15
TN - Tunisia 15
BG - Bulgaria 13
BO - Bolivia 13
HR - Croazia 13
SK - Slovacchia (Repubblica Slovacca) 13
DO - Repubblica Dominicana 12
JM - Giamaica 11
LB - Libano 11
UY - Uruguay 11
KG - Kirghizistan 10
OM - Oman 10
AL - Albania 9
RS - Serbia 9
BH - Bahrain 8
CR - Costa Rica 8
EU - Europa 8
LV - Lettonia 8
NO - Norvegia 8
PS - Palestinian Territory 8
QA - Qatar 8
SN - Senegal 8
DK - Danimarca 7
SI - Slovenia 7
A2 - ???statistics.table.value.countryCode.A2??? 6
AM - Armenia 6
ET - Etiopia 6
HN - Honduras 6
KZ - Kazakistan 6
NZ - Nuova Zelanda 6
PA - Panama 6
TH - Thailandia 6
BY - Bielorussia 5
KW - Kuwait 5
SV - El Salvador 5
SY - Repubblica araba siriana 5
BW - Botswana 4
CI - Costa d'Avorio 4
EE - Estonia 4
Totale 64.583
Città #
Southend 4.776
Singapore 3.760
Ashburn 2.594
Moscow 2.468
Jacksonville 2.237
Chandler 2.205
San Jose 2.104
Dallas 1.777
Hong Kong 1.430
Woodbridge 1.234
Dublin 1.047
Ann Arbor 959
Verona 794
The Dalles 724
Beijing 705
Houston 695
Ho Chi Minh City 451
Lawrence 447
Princeton 447
Los Angeles 435
New York 428
Wilmington 424
Jinan 329
Nanjing 297
Hanoi 292
Shenyang 281
Redmond 238
Buffalo 228
Helsinki 215
Bologna 210
Milan 207
Tokyo 184
Tianjin 182
Sindelfingen 178
Hebei 175
Munich 167
São Paulo 161
Redondo Beach 159
Changsha 136
Columbus 129
Abuja 128
Santa Clara 125
Ningbo 113
Zhengzhou 113
Boardman 112
Haikou 109
Nanchang 108
Rome 100
Hangzhou 96
Warsaw 94
London 93
Orem 92
Jiaxing 90
Taizhou 88
Guangzhou 87
Seattle 86
Chicago 77
Denver 77
San Francisco 76
Redwood City 72
Brussels 69
Frankfurt am Main 69
Taiyuan 69
Falkenstein 65
Norwalk 65
Council Bluffs 62
Brooklyn 60
Washington 59
Montreal 58
Turku 58
Da Nang 55
Phoenix 55
Johannesburg 52
Chennai 51
Falls Church 51
Amsterdam 50
Hyderabad 49
Rio de Janeiro 49
Belo Horizonte 48
Fairfield 48
Toronto 48
Atlanta 47
Brasília 45
Tashkent 45
Vienna 45
Jakarta 44
Stockholm 44
Fuzhou 43
Lomé 43
Dearborn 42
Lanzhou 42
Manchester 42
Biên Hòa 41
Boston 41
Dong Ket 41
Mexico City 40
Orani 40
Cotonou 39
Poplar 39
Seoul 39
Totale 39.837
Nome #
Epidemiology and Economic Burden of Osteoporosis in Italy 435
Fibromialgia. Razionale e risultati del trattamento con L-Acetilcarnitina. 422
Teriparatide and denosumab combination therapy and skeletal metabolism 343
Epidemiology of mastocytosis in adults based on a multidisciplinary diagnostic approach. 331
Artrite Reumatoide e Metabolismo Minerale 269
[The long term correction of vitamin D deficiency: comparison between different treatments with vitamin D in clinical practice.]. 265
A case of adult chronic recurrent multifocal osteomyelitis successfully treated with neridronate 264
Acute Phase Response After Zoledronic Acid is Associated with Long-Term Effects on White Blood Cells. 259
Long-term effects of amino-bisphosphonates on circulating gamma-delta T cells 252
CD14(++) CD16(-) monocytes are the main source of 11β-HSD type 1 after IL-4 stimulation 252
The effects of menopause and estrogen replacement therapy on the renal handling of calcium 239
Anti-CCP antibodies and bone 239
Association of CTR and COLIA1 alleles with BMD values in peri and postmenopausal women 237
Gender differences in clinical features and quality of life of patients with axial spondyloarthritis and psoriatic arthritis 233
Age-related bone loss in postmenopausal women 232
[Therapeutic strategies in osteoporosis: whom and when to treat] 230
[Diphosphonates: and alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate] 227
La correzione dell’ipovitaminosi D nel lungo termine: confronto tra diverse modalità di somministrazione di vitamina D nella pratica clinica. 227
Trattamento dell'osteoporosi cortisonica con Nandrolone Decanoato 226
Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis 224
Clonal mast cell disorders limited to bone marrow: not a negligible disease. 224
Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women 221
Bone Metabolism in a Large Cohort of Patients with Systemic Sclerosis 218
Bone metabolism in patients with anorexia nervosa and amenorrhoea 218
[Risk factors for hip fracture in elderly persons]. 216
Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis 212
AB0776 18F-Fluoride PET/CT for Detection of Axial Involvement in Ankylosing Spondylitis: 210
Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. 209
Hajdu Cheney Syndrome; report of a novel NOTCH2 mutation and treatment with denosumab 209
Bone mineral density and bone turnover in premenopausal women with rheumatoid arthritis 206
Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed 'window of opportunity' 206
Longitudinal Evaluation of Bone Mineral Density and Bone Metabolism Markers in Patients with Indolent Systemic Mastocytosis Without Osteoporosis 205
Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes 205
A case of mandible Paget’s disease of the bone treated with intravenous neridronate 204
Clinical profile and outcome of patients with rheumatoid arthritis and abnormally high aortic stiffness 203
The genetic background of osteoporosis in cystic fibrosis: association analysis with polymorphic markers in four candidate genes 202
[Study of vitamin D status of rheumatoid arthritis patients. Rationale and design of a cross-sectional study by the osteoporosis and metabolic bone diseases study group of the Italian Society of Rheumatology (SIR)]. 202
Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels 202
Amino-Bisphosphonates and Cardiovascular Risk: A New Hypothesis Involving the Effects on Gamma-Delta T Cells 201
Bone involvement and osteoporosis in mastocytosis. 200
Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis 200
Value of flow cytometry in the diagnosis of indolent systemic mastocytosis. 198
Incidenza di ipovitaminosi D nel Nord Italia 197
Bisphosphonates vs infliximab in ankylosing spondylitis treatment. 197
18F-fluoride PET/CT for detection of axial involvement in ankylosing spondylitis: correlation with disease activity 196
Concentric left ventricular remodelling is associated with subclinical systolic dysfunction in patients with psoriatic arthritis 194
Comment on: clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial 191
Prevalence and incidence of rheumatoid arthritis in Italy. 188
Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study 188
Teriparatide Treatment in Adult Patients with Osteogenesis Imperfecta Type I. 187
Circulating Dickkopf-1 and sclerostin in patients with Paget's disease of bone 187
Acute Effects of Glucocorticoid Treatment, TNFα or IL-6R Blockade on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis: A Pilot Study 187
Bone involvement in patient with clonal mast cell disorders 186
Could γ\δ T-cells explain zoledronic acid adverse events? 186
Combined Circumferential and Longitudinal Left Ventricular Systolic Dysfunction in Patients with Rheumatoid Arthritis without Overt Cardiac Disease 184
New strategies for the prevention and treatment of systemic and local bone loss; from pathophysiology to clinical application 184
Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone 183
Effects of TNF Inhibitors on Parathyroid Hormone and Wnt Signaling Antagonists in Rheumatoid Arthritis 183
Serum Levels of Tryptase Suggest That Mast Cells Might Have an Antiinflammatory Role in Rheumatoid Arthritis: Comment on the Article by Rivellese et al 181
Association Between Short-term Exposure to Environmental Air Pollution and Psoriasis Flare 181
Correction to: Is the exposure to bisphosphonates or osteoporosis the predictor of spinal radiographic progression in ankylosing spondylitis? 179
Prednisone compared to methysprednisolone in the polymyalgia rheumatica treatment 176
Allergy and the bone: unexpected relationships 176
[Use of nonsteroidal anti-inflammatory drugs in patients with vertebral osteoporotic fractures]. 176
An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis 176
Guidelines for the diagnosis, prevention and management of osteoporosis 175
Adherence to therapeutic and diagnostic recommendations in patients with femur fracture and at risk of re-fracture or death: results of an analysis of administrative databases. 174
Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series 174
Rapporti tra sistema immune e metabolismo osseo 172
Osteoporosis treatment: why ibandronic acid? 172
Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study 172
Higher Level of Dickkopf-1 is Associated with Low Bone Mineral Density and Higher Prevalence of Vertebral Fractures in Patients with Ankylosing Spondylitis 171
Clinical utility of a wheat-germ precipitation assay for determination of bone alkaline phosphatase concentrations in patients with different metabolic bone diseases 170
Cancer in adult patients with inflammatory arthritis is associated with high ascending aortic stiffness and left ventricular hypertrophy and diastolic dysfunction 170
Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis. 169
ARTROPATIE DISMETABOLICHE 168
Osteoporosis and fractures in systemic vasculitides: a systematic review and meta-analysis 167
A multi-dimensional questionnaire quantifying quality of life in elderly osteoporotic women: the Italian triple-Q osteoporosis study 167
DXA bone mineral density in males: retrospective study in real life. 166
Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis 166
Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis 166
Sclerostin and DKK1 in postmenopausal osteoporosis treated with Denosumab. 166
Dickkopf-1 and sclerostin serum levels in patients with systemic mastocytosis 165
Bone Disease in Mastocytosis 165
Association between long-term exposure to air pollution and immune-mediated diseases: a population-based cohort study 165
Dose-dependent short-term effects of single high doses of oral vitamin D3 on bone turnover markers 164
In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls 164
Depression is associated with increased disease activity and higher disability in a large Italian cohort of patients with rheumatoid arthritis 164
Coping strategies, emotional distress and perceived disease severity in a cohort of patients with rheumatoid arthritis: a mediation analysis 162
Regulation of calcium-parathyroid hormone feedback in primary hyperparathyroidism: effects of bisphosphonate treatment 162
Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis 162
Are aortic coarctation and rheumatoid arthritis different models of aortic stiffness? Data from an echocardiographic study 162
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases 162
Clinical profile and outcome of patients with chronic inflammatory arthritis and metabolic syndrome 160
Effects of denosumab on peripheral lymphocyte subpopulations 160
Artropatie degenerative 159
Sclerostin and DKK1 in primary hyperparathyroidism. 159
Adherence to alendronic or risedronic acid treatment, combined or not to calcium and vitamin D, and related determinants in Italian patients with osteoporosis 159
Rituximab increases peripheral natural killer cells in patients with rheumatoid arthritis 158
Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations 158
Totale 20.035
Categoria #
all - tutte 217.200
article - articoli 207.788
book - libri 0
conference - conferenze 3.095
curatela - curatele 0
other - altro 639
patent - brevetti 0
selected - selezionate 0
volume - volumi 5.678
Totale 434.400


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021625 0 0 0 0 0 0 0 0 0 27 440 158
2021/20223.269 238 807 49 158 155 128 61 185 278 97 305 808
2022/20236.835 560 555 703 1.180 607 1.652 86 384 732 75 226 75
2023/20243.514 179 270 330 418 403 534 180 274 58 128 494 246
2024/20259.554 564 679 406 1.475 472 257 444 469 1.414 810 701 1.863
2025/202625.690 1.946 1.344 1.991 4.359 6.477 1.888 2.731 1.610 2.046 1.298 0 0
Totale 65.466